CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development.    The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.   CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate.   CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business of Cardinal Health, Inc. (CAH). The spin-off was completed in September ...

Cardinal Health, Inc. (CAH) yesterday entered into a five-year, laboratory products supply agreement with Novation, one of the largest group purchasing organizations (GPOs) in the U.S. Per the agreement, Cardinal Health will exclusively provide laboratory products to Novation's clinical members, such as hospital laboratories, blood banks, core laboratories and reference laboratories. The agreement is effective from Oct. 1, 2009 and runs until 2014. Financial terms of the agreement have not been disclosed. Cardinal’s stock reacted positively to the news, with the price increasing roughly 1.4% to $27.70 at the end of Sept. 28, 2009. Cardinal Health is one of the largest global healthcare companies which helps pharmacies, hospitals and ambulatory care sites to focus on low-cost patient care. The company is also a leading manufacturer of medical and surgical products. Cardinal Health recently completed the spin-off of its Clinical and Medical Products business to form ...

Cardinal Health, Inc. (CAH) has completed the spin-off of its Clinical and Medical Products business to form a subsidiary, CareFusion Corporation (CFN). The spin-off was completed through a pro rata distribution of roughly 81% of CareFusion’s common stock. Roughly 222 million shares of CareFusion common stock were outstanding on the date of distribution. Of this, 180 million shares (81%) were distributed to Cardinal Health shareholders on a pro rata basis. Cardinal Health retained the balance 41 million shares, which will be divested within the next five years. Cardinal Health shareholders received 0.5 share of CareFusion common stock for each share of Cardinal Health they hold. We think that the spin-off will help Cardinal Health unlock the value of the assets tied to CareFusion and concentrate more on its core Healthcare Supply Chain business. The company’s core Healthcare business constitutes roughly 96% of total revenues....

Cardinal Health Inc. (CAH) announced that the use of the preoperative skin preparation, ChloraPrep, is significantly more effective than both DuraPrep and povidone-iodine at eliminating overall bacteria from the shoulder region. After antisepsis with ChloraPrep, only 7% of skin cultures tested positive for bacteria compared to 19% for DuraPrep and 31% for povidone-iodine.   The data was published by The Journal of Bone and Joint Surgery recently. ChloraPrep is a product of Cardinal Health’s subsidiary, CareFusion, which the company will spin-off with effect from Aug 31.   ChloraPrep is a preoperative skin preparation that reduces bacteria and other microorganisms on the patients' skin before any medical and surgical procedures. The drug remains effective for at least 48 hours after its application and reduces the risk of dangerous bloodstream and surgical site infections.    Bacteria on the skin is the primary cause of surgical site infections. These infections ...

Cardinal Health Inc. (CAH) announced that its spin-off subsidiary, CareFusion Corp., will be included in the S&P 500 after the close of trading on Aug 31. CareFusion replaces The Manitowoc Co. Inc. (MTW) in the index and will be added to the S&P 500 GICS (Global Industry Classification Standard) Health Care Equipment Sub-Industry index.   CareFusion is being formed by spinning off the Clinical and Medical Products business of Cardinal Health. The spin-off is expected to be completed on Aug 31. CareFusion Corp. is expected to generate earnings per share of $1.10 to $1.20 on a standalone basis.   The S&P 500 represents prices of the top 500 large-cap companies traded in the U.S. stock exchanges. It is one of the world’s most prestigious indices. Hundreds of billions of US dollars are invested in the S&P 500 index by different mutual funds, pension funds and exchange traded ...

Cardinal Health Inc. (CAH) sees a 15% drop in its core earnings during 2010 if results from its clinical and medical products segment are eliminated from the comparison.

Shares are down nearly 11% today.

The health care products and services company aims to spin off its CareFusion segment early in its 2010 fiscal year.

For the fiscal year ending Jun 30, Cardinal Health projects earnings, eliminating the division, between $2.20 and $2.25.

Analysts are expecting earnings per share of $3.51 for the current fiscal year. That's down from $3.55 2 months ago.

The company also announced that it would raise its quarterly dividend to 17.5 cents, an increase of 25% from 14 cents.

This Zacks #4 Rank ("Sell") company is moving on heavy volume of 11 million shares, versus the daily average of 1.5 million.

"CAH" Free Stock Analysis: Buy? Sell? Hold?Zacks ...

Cardinal Health Inc. (CAH) is up about 1.5% this afternoon on volume of 983,000 shares, against the average of 1.7 million.

Cardinal Health recently announced that it sees 2009 EPS at the low end of its prior forecast range between $3.50 and $3.60 per share.

Meanwhile, 10 of the 13 analysts revised downward in the last month, sending the full-year consensus to $3.51 per share from $3.54.

In the same time period, the average forecast for 2010 has dropped to $3.68 from $3.86 per share, as 8 analysts out of 11 cut estimates.

Cardinal Health is a Zacks #4 Rank ("Sell") stock.

"CAH" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

The global pharmaceutical industry is an often-overlooked sector. David Fessler of Investment U shows us one of the biggest players on the market.

He says that, “ while few other sectors can boast recession resilience, the health care sector is proving to be a sector that should be part of everyone’s portfolio…”

This from David:

Several weeks ago, we focused on the distribution side of the health care industry as yet another overlooked area that should continue to do well during our economic downturn.

We discussed one of the largest “Grainger-like” companies in the health care industry, Cardinal Health, Inc. (NYSE: CAH). Cardinal is an $87 billion global manufacturer, supplier and distributor of medical products.

Given the sheer size of the medical equipment and drug market - the global pharmaceutical market alone is estimated to be north of $700 billion annually - it shouldn’t be too surprising that Cardinal

...

AmerisourceBergen Corporation: Increase the “Health” of your Portfolio

by David Fessler, Advisory Panelist

Several weeks ago, we focused on the distribution side of the health care industry as yet another overlooked area that should continue to do well during our economic downturn.

We discussed one of the largest “Grainger-like” companies in the health care industry, Cardinal Health, Inc. (NYSE: CAH). Cardinal is an $87 billion global manufacturer, supplier and distributor of medical products.

Given the sheer size of the medical equipment and drug market - the global pharmaceutical market alone is estimated to be north of $700 billion annually - it shouldn’t be too surprising that Cardinal has a competitor or two…

One of its biggest is AmerisourceBergen Corporation (NYSE: ABC), a large, global pharmaceutical services company with operations in Canada, Great Britain and the United States.

AmerisourceBergen Corporation’s Products & Services

AmerisourceBergen Corporation was

...

Investing in Crude Oil: The Best Way to Play Oil’s Imminent Rebound

by Louis Basenese, Advisory Panelist
Senior Analyst, The Oxford Club

Billionaire investor George Soros and I don’t normally see eye to eye. He supports drug decriminalization, assisted suicide, America bashing… and a host of other off-the-reserve liberal causes.

I don’t. I’m an old-school Reagan conservative. (Full disclosure – I’m so old school, I named my first born after the late President.)

But here’s the thing. When it comes to investing, great political divides matter little. Because it’s not about getting our guy elected or unashamedly pushing a partisan agenda.

Instead, business – and by extension, investing in businesses – is only about increasing profits, as Milton Friedman put it. And based on the latest SEC filing for Soros’ hedge fund, we both agree on the best way for investing in crude oil’s imminent rebound…

Interested in Making Money

…